AI is speeding up drug and medical discoveries in biotech, but one major bottleneck to ensuring patients get access to these innovative therapies quickly is the slow process of clinical trials.
Now, Microsoft and German drugmaker Boehringer Ingelheim are teaming up to accelerate the process using AI-powered digital patient twins. These are computational representations of individual patients where clinicians can test how a disease might progress and how outcomes might change under different scenarios.
Their goal is to see if AI could reduce the number of human patients needed in conventional control groups and accelerate the generation of clinical evidence.
The research will explore ways to predict how diseases progress and how patients may respond to treatment, as well as new methods for simulating clinical trials. It will also examine whether existing patient data could partly or fully replace a traditional control group in some trials.
“The research may help reduce the number of patients required in control groups, accelerate the generation of clinical evidence, and improve clinical trial design,” Boehringer Ingelheim said in a statement.
The companies said the work will begin in lung health and examine disease-progression modeling, predictive outcome modeling and advanced trial simulation across multiple disease and therapeutic areas. They also are exploring possible projects in animal health, business processes and technology infrastructure.